Ionis Pharmaceuticals Inc (NASDAQ: IONS)’s stock price has decreased by -9.65 compared to its previous closing price of 30.17. However, the company has seen a -15.53% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-03-31 that CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 Bank of America 2025 Health Care Conference on Wednesday, May 14, 2025 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025 A live webcast of these presentations can be accessed on the Investors & Media secti.
Is It Worth Investing in Ionis Pharmaceuticals Inc (NASDAQ: IONS) Right Now?
Company’s 36-month beta value is 0.29.Analysts have differing opinions on the stock, with 13 analysts rating it as a “buy,” 4 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for IONS is 154.59M, and currently, short sellers hold a 8.29% ratio of that floaft. The average trading volume of IONS on April 02, 2025 was 1.63M shares.
IONS’s Market Performance
IONS stock saw a decrease of -15.53% in the past week, with a monthly decline of -16.38% and a quarterly a decrease of -24.09%. The volatility ratio for the week is 4.54%, and the volatility levels for the last 30 days are 4.31% for Ionis Pharmaceuticals Inc (IONS). The simple moving average for the past 20 days is -16.15% for IONS’s stock, with a -30.48% simple moving average for the past 200 days.
Analysts’ Opinion of IONS
Many brokerage firms have already submitted their reports for IONS stocks, with Redburn Atlantic repeating the rating for IONS by listing it as a “Neutral.” The predicted price for IONS in the upcoming period, according to Redburn Atlantic is $39 based on the research report published on March 31, 2025 of the current year 2025.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see IONS reach a price target of $60, previously predicting the price at $67. The rating they have provided for IONS stocks is “Market Perform” according to the report published on August 02nd, 2024.
Leerink Partners gave a rating of “Outperform” to IONS, setting the target price at $62 in the report published on July 24th of the previous year.
IONS Trading at -15.94% from the 50-Day Moving Average
After a stumble in the market that brought IONS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.92% of loss for the given period.
Volatility was left at 4.31%, however, over the last 30 days, the volatility rate increased by 4.54%, as shares sank -17.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.27% lower at present.
During the last 5 trading sessions, IONS fell by -15.53%, which changed the moving average for the period of 200-days by -34.31% in comparison to the 20-day moving average, which settled at $32.51. In addition, Ionis Pharmaceuticals Inc saw -22.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IONS starting from Monia Brett P, who sale 140 shares at the price of $32.32 back on Mar 11 ’25. After this action, Monia Brett P now owns 180,980 shares of Ionis Pharmaceuticals Inc, valued at $4,525 using the latest closing price.
Monia Brett P, the Officer of Ionis Pharmaceuticals Inc, proposed sale 140 shares at $32.32 during a trade that took place back on Mar 11 ’25, which means that Monia Brett P is holding shares at $4,525 based on the most recent closing price.
Stock Fundamentals for IONS
Current profitability levels for the company are sitting at:
- -0.67 for the present operating margin
- 0.97 for the gross margin
The net margin for Ionis Pharmaceuticals Inc stands at -0.64. The total capital return value is set at -0.18. Equity return is now at value -93.03, with -15.13 for asset returns.
Based on Ionis Pharmaceuticals Inc (IONS), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35. The debt to equity ratio resting at 2.41. The interest coverage ratio of the stock is -5.53.
Currently, EBITDA for the company is -475.08 million with net debt to EBITDA at -3.28. When we switch over and look at the enterprise to sales, we see a ratio of 7.81. The receivables turnover for the company is 7.65for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.47.
Conclusion
In a nutshell, Ionis Pharmaceuticals Inc (IONS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
